Pyruvate dehydrogenase E3-binding protein deficiency

Pyruvate dehydrogenase E3-binding protein deficiency (also known as component X deficiency or dihydrolipoamide dehydrogenase-binding protein deficiency) is a rare inherited metabolic disorder caused by mutations in the PDHX gene (previously known as DLDBP), which encodes the E3-binding protein (E3BP, formerly called protein X) of the pyruvate dehydrogenase complex (PDC). The E3-binding protein is essential for anchoring the E3 (dihydrolipoamide dehydrogenase) component to the PDC core, and its deficiency leads to impaired conversion of pyruvate to acetyl-CoA. This results in energy deficiency, particularly affecting tissues with high energy demands such as the brain and nervous system, and leads to accumulation of lactic acid in the blood. Clinical features typically present in infancy or early childhood and include lactic acidosis, developmental delay, intellectual disability, hypotonia, seizures, and structural brain abnormalities. Neuroimaging may reveal abnormalities of the corpus callosum, basal ganglia, or white matter changes resembling Leigh syndrome. The severity of the condition is variable, ranging from severe neonatal lactic acidosis to milder forms with predominantly neurological involvement. Some patients may exhibit episodic metabolic decompensation triggered by illness or metabolic stress. Treatment is largely supportive and aimed at managing metabolic acidosis and optimizing residual PDC activity. A ketogenic diet, which provides an alternative energy source (ketone bodies) that bypasses the PDC, is a mainstay of dietary management. Thiamine (vitamin B1) supplementation may be trialed, as some PDC deficiencies show partial thiamine responsiveness, though the response in E3BP deficiency specifically is variable. Dichloroacetate has been used in some cases to reduce lactate levels by stimulating PDC activity. Despite these interventions, neurological outcomes remain guarded, and long-term prognosis depends on the severity of the enzymatic deficiency and the degree of neurological involvement.

Common questions about Pyruvate dehydrogenase E3-binding protein deficiency